• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AstraZeneca to acquire Almirall’s respiratory franchise

AstraZeneca to acquire Almirall’s respiratory franchise

July 31, 2014
CenterWatch Staff

Barcelona-based Almirall has entered an agreement to transfer its respiratory franchise to AstraZeneca for an initial consideration of $875 million on completion and up to $1.22 billion in development, launch and sales-related milestones. AZ also has agreed to make various sales-related payments.

AZ will own the rights for the development and commercialization of Almirall's existing proprietary respiratory business, including rights to revenues from Almirall's existing partnerships, as well as its pipeline of investigational novel therapies.  The franchise includes Eklira(aclidinium); LAS40464, the combination of aclidinium with formoterol, which has been filed for registration in the E.U. and is being developed in the U.S.; LAS100977 (abediterol), a once-daily, long-acting beta2-agonist (LABA) in phase II; an M3 antagonist beta2-agonist (MABA) platform in preclinical development (LAS191351, LAS194871) and phase I (LAS190792); and multiple preclinical programs.

Almirall Sofotec, an Almirall subsidiary focused on the development of innovative proprietary devices, also will transfer to AZ.

Almirall's pipeline of novel respiratory assets and its device capabilities further strengthen AZ's respiratory portfolio, which includes Symbicort and Pulmicort, as well as the company's investigational medicines in development. The addition of aclidinium and the combination of aclidinium with formoterol, both in proprietary Genuair device, will allow AZ to offer patients a choice between dry powder inhaler and metered dose inhaler devices across a range of molecules and combinations.

Almirall and AZ anticipate that, subject to local consultation and legislation, a significant number of employees dedicated to the respiratory business, including Almirall Sofotec employees, will transfer to AZ.

Subject to anti-trust and competition clearances, customary terms and conditions, the companies anticipate the transaction to complete by the end of 2014.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing